CN101874020B - 作为毒蕈碱受体激动剂的哌啶衍生物 - Google Patents
作为毒蕈碱受体激动剂的哌啶衍生物 Download PDFInfo
- Publication number
- CN101874020B CN101874020B CN2008801155657A CN200880115565A CN101874020B CN 101874020 B CN101874020 B CN 101874020B CN 2008801155657 A CN2008801155657 A CN 2008801155657A CN 200880115565 A CN200880115565 A CN 200880115565A CN 101874020 B CN101874020 B CN 101874020B
- Authority
- CN
- China
- Prior art keywords
- piperidin
- methyl
- hexahydro
- benzimidazol
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CS(OC[C@@]1[C@@](*)CCCC1)(=O)=O Chemical compound CS(OC[C@@]1[C@@](*)CCCC1)(=O)=O 0.000 description 5
- QDPUXYAYDGHACK-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(C)N(CC1)CCC1=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(C)N(CC1)CCC1=O)=O QDPUXYAYDGHACK-UHFFFAOYSA-N 0.000 description 1
- SXWLQNQPKHNIHK-IBGZPJMESA-N CC(C)(C)OC(N(CC1)CCC1(C)N(CC1)CCC1N[C@@H](CCCC1)C1=N)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(C)N(CC1)CCC1N[C@@H](CCCC1)C1=N)=O SXWLQNQPKHNIHK-IBGZPJMESA-N 0.000 description 1
- XUFBETUUQRMWRY-YHMJZVADSA-N CC(C)(C)OC(NC1[C@@H](CO)CCCC1)=O Chemical compound CC(C)(C)OC(NC1[C@@H](CO)CCCC1)=O XUFBETUUQRMWRY-YHMJZVADSA-N 0.000 description 1
- GBBOZVGWCUJZSV-HZPDHXFCSA-N CC1(CCNCC1)N(CC1)CCC1N([C@H](CCCC1)[C@@H]1N1)C1=O Chemical compound CC1(CCNCC1)N(CC1)CCC1N([C@H](CCCC1)[C@@H]1N1)C1=O GBBOZVGWCUJZSV-HZPDHXFCSA-N 0.000 description 1
- JVYQKKGONMWXNA-UHFFFAOYSA-N CCOC(N(CC1)CC1(C)N(CC1)CCC1=O)=O Chemical compound CCOC(N(CC1)CC1(C)N(CC1)CCC1=O)=O JVYQKKGONMWXNA-UHFFFAOYSA-N 0.000 description 1
- VVSNTZLQTPWKEH-YGYNJSFOSA-N CCOC(N(CC1)CC1(C)N(CC1)CCC1N[C@@H](CCCC1)[C@H]1N)=O Chemical compound CCOC(N(CC1)CC1(C)N(CC1)CCC1N[C@@H](CCCC1)[C@H]1N)=O VVSNTZLQTPWKEH-YGYNJSFOSA-N 0.000 description 1
- DQYGBMLEVQLDQC-UHFFFAOYSA-N CCOC(N(CC1)CC1=O)=O Chemical compound CCOC(N(CC1)CC1=O)=O DQYGBMLEVQLDQC-UHFFFAOYSA-N 0.000 description 1
- DFEKGQNQRWMVDC-ZTVINCFESA-N CC[C@@H](CCCC1)[C@H]1NC(CC1)CCN1C(C)(CC1)CN1C(OC(C)(C)C)=O Chemical compound CC[C@@H](CCCC1)[C@H]1NC(CC1)CCN1C(C)(CC1)CN1C(OC(C)(C)C)=O DFEKGQNQRWMVDC-ZTVINCFESA-N 0.000 description 1
- NRKTXEAGANNPCF-ZTVINCFESA-N C[C@@H](CCCC1)[C@H]1N(C)C(CC1)CCN1C(C)(CC1)CN1C(OC(C)(C)C)=O Chemical compound C[C@@H](CCCC1)[C@H]1N(C)C(CC1)CCN1C(C)(CC1)CN1C(OC(C)(C)C)=O NRKTXEAGANNPCF-ZTVINCFESA-N 0.000 description 1
- VFTVSKOQPNJGLH-QJNHQHDKSA-N C[C@@H]1[C@@H](CC(NC(CC2)CCN2C2(C)CN(C)CC2)=O)CCCC1 Chemical compound C[C@@H]1[C@@H](CC(NC(CC2)CCN2C2(C)CN(C)CC2)=O)CCCC1 VFTVSKOQPNJGLH-QJNHQHDKSA-N 0.000 description 1
- SSJXIUAHEKJCMH-WDSKDSINSA-N N[C@@H](CCCC1)[C@H]1N Chemical compound N[C@@H](CCCC1)[C@H]1N SSJXIUAHEKJCMH-WDSKDSINSA-N 0.000 description 1
- ZYZCHUMYNSXZQK-SFYZADRCSA-N N[C@@H]1[C@@H](CC#N)CCCC1 Chemical compound N[C@@H]1[C@@H](CC#N)CCCC1 ZYZCHUMYNSXZQK-SFYZADRCSA-N 0.000 description 1
- TYAOCPIDXZHTIG-YFKPBYRVSA-N N[C@@H]1[IH]CCCC1 Chemical compound N[C@@H]1[IH]CCCC1 TYAOCPIDXZHTIG-YFKPBYRVSA-N 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N OC1CCNCC1 Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97128807P | 2007-09-11 | 2007-09-11 | |
| US60/971,288 | 2007-09-11 | ||
| PCT/GB2008/050802 WO2009034380A1 (en) | 2007-09-11 | 2008-09-09 | Piperidine derivatives as agonists of muscarinic receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101874020A CN101874020A (zh) | 2010-10-27 |
| CN101874020B true CN101874020B (zh) | 2012-11-07 |
Family
ID=40011174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008801155657A Expired - Fee Related CN101874020B (zh) | 2007-09-11 | 2008-09-09 | 作为毒蕈碱受体激动剂的哌啶衍生物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8119661B2 (https=) |
| EP (1) | EP2197843B1 (https=) |
| JP (1) | JP2010539151A (https=) |
| KR (1) | KR20100052528A (https=) |
| CN (1) | CN101874020B (https=) |
| AR (1) | AR071245A1 (https=) |
| AT (1) | ATE539056T1 (https=) |
| AU (1) | AU2008299604A1 (https=) |
| BR (1) | BRPI0816331A2 (https=) |
| CA (1) | CA2699286A1 (https=) |
| CL (1) | CL2008002689A1 (https=) |
| ES (1) | ES2377772T3 (https=) |
| MX (1) | MX2010002584A (https=) |
| PE (1) | PE20091090A1 (https=) |
| RU (1) | RU2010110036A (https=) |
| TW (1) | TW200924766A (https=) |
| UY (1) | UY31334A1 (https=) |
| WO (1) | WO2009034380A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200815405A (en) * | 2006-06-09 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
| TW200813018A (en) * | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
| US20090221642A1 (en) * | 2008-03-03 | 2009-09-03 | Astrazeneca Ab | Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176 |
| US20090275574A1 (en) * | 2008-05-05 | 2009-11-05 | Astrazeneca Ab | Novel compounds-300 |
| EP2780015B1 (en) * | 2011-11-18 | 2017-01-04 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| CN107098899B (zh) * | 2012-09-18 | 2019-09-06 | 赫普泰雅治疗有限公司 | 作为毒蕈碱的m1受体激动剂的二环氮杂化合物 |
| JP6478923B2 (ja) | 2013-02-07 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート |
| GB2519470A (en) * | 2013-09-18 | 2015-04-22 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic M1 receptor agonists |
| SG11201606269WA (en) | 2014-02-06 | 2016-09-29 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997016192A1 (en) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine antagonists |
| WO2005042517A2 (en) * | 2003-11-03 | 2005-05-12 | Schering Corporation | Bipiperidinyl derivatives useful as inhibitors of chemokine receptors |
| WO2007036711A1 (en) * | 2005-09-30 | 2007-04-05 | Glaxo Group Limited | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0029707B1 (en) | 1979-11-21 | 1984-02-01 | Kyowa Hakko Kogyo Co., Ltd | Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them |
| DE4302051A1 (de) | 1993-01-26 | 1994-07-28 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| EP0714299B1 (en) | 1993-07-16 | 2002-04-24 | Merck & Co. Inc. | Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists |
| JP2002515008A (ja) | 1994-10-27 | 2002-05-21 | メルク エンド カンパニー インコーポレーテッド | ムスカリン・アンタゴニスト |
| US5756508A (en) | 1995-10-31 | 1998-05-26 | Merck & Co., Inc. | Muscarine antagonists |
| US5756497A (en) | 1996-03-01 | 1998-05-26 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| SK285631B6 (sk) | 1996-09-10 | 2007-05-03 | Dr. Karl Thomae Gmbh | Modifikované aminokyseliny, farmaceutický prostriedok s ich obsahom a ich použitie |
| JPH10158192A (ja) | 1996-10-03 | 1998-06-16 | Eisai Co Ltd | 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物 |
| SE9704546D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| AU2307999A (en) | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| AU1679099A (en) | 1998-01-19 | 1999-08-02 | Pfizer Inc. | 4-(2-keto-1-benzimidazolinyl)piperidine compounds as orl1-receptor agonists |
| MA26659A1 (fr) | 1998-08-06 | 2004-12-20 | Pfizer | Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation. |
| JP2000323278A (ja) | 1999-05-14 | 2000-11-24 | Toray Ind Inc | 発光素子 |
| US6699880B1 (en) | 1999-10-13 | 2004-03-02 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
| SE9904652D0 (sv) | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
| EP1309593B1 (en) | 2000-08-14 | 2006-03-15 | Ortho-McNeil Pharmaceutical, Inc. | Substituted pyrazoles |
| JP2002302675A (ja) | 2001-04-06 | 2002-10-18 | Fuji Photo Film Co Ltd | 液晶組成物、それを用いた液晶素子およびアゾ化合物 |
| EP1385518B1 (en) | 2001-04-18 | 2008-08-06 | Euro-Celtique S.A. | Benzimidazolone compounds |
| IL158484A0 (en) | 2001-04-18 | 2004-05-12 | Euro Celtique Sa | Nociceptin analogs |
| JPWO2002085890A1 (ja) | 2001-04-20 | 2004-08-12 | 萬有製薬株式会社 | ベンズイミダゾロン誘導体 |
| AR036366A1 (es) * | 2001-08-29 | 2004-09-01 | Schering Corp | Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit |
| WO2004089942A2 (en) | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| CA2465328C (en) | 2001-11-01 | 2011-06-14 | Michael Francis Gross | Piperidines |
| NZ535763A (en) | 2002-04-18 | 2007-06-29 | Schering Corp | (1-4-piperidinyl) benzimidazole derivatives useful as histamine H3 antagonists |
| EP1515722A4 (en) | 2002-06-17 | 2006-06-21 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA |
| WO2004069828A1 (ja) | 2003-02-04 | 2004-08-19 | Mitsubishi Pharma Corporation | ピペリジン化合物およびその医薬用途 |
| MXPA05011523A (es) | 2003-04-30 | 2006-01-23 | Inst For Pharm Discovery Inc | Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas. |
| US20050228023A1 (en) | 2003-12-19 | 2005-10-13 | Sri International | Agonist and antagonist ligands of the nociceptin receptor |
| JP2007515429A (ja) | 2003-12-19 | 2007-06-14 | エリクシアー ファーマシューティカルズ， インコーポレイテッド | 障害を治療する方法 |
| KR20070034524A (ko) | 2004-05-28 | 2007-03-28 | 버텍스 파마슈티칼스 인코포레이티드 | 무스카린 수용체 조정자 |
| US8143404B2 (en) | 2004-09-13 | 2012-03-27 | Ono Pharmaceutical Co., Ltd | Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient |
| WO2006037052A2 (en) | 2004-09-27 | 2006-04-06 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Modulating mxa expression |
| WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| WO2006130469A1 (en) | 2005-05-27 | 2006-12-07 | Oregon Health & Science University | Stimulation of neurite outgrowth by small molecules |
| TW200813018A (en) * | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
-
2008
- 2008-09-08 US US12/205,968 patent/US8119661B2/en not_active Expired - Fee Related
- 2008-09-09 ES ES08806636T patent/ES2377772T3/es active Active
- 2008-09-09 KR KR1020107005282A patent/KR20100052528A/ko not_active Withdrawn
- 2008-09-09 RU RU2010110036/04A patent/RU2010110036A/ru unknown
- 2008-09-09 CN CN2008801155657A patent/CN101874020B/zh not_active Expired - Fee Related
- 2008-09-09 EP EP08806636A patent/EP2197843B1/en not_active Not-in-force
- 2008-09-09 MX MX2010002584A patent/MX2010002584A/es not_active Application Discontinuation
- 2008-09-09 CA CA2699286A patent/CA2699286A1/en not_active Abandoned
- 2008-09-09 AU AU2008299604A patent/AU2008299604A1/en not_active Abandoned
- 2008-09-09 JP JP2010524582A patent/JP2010539151A/ja active Pending
- 2008-09-09 BR BRPI0816331 patent/BRPI0816331A2/pt not_active Application Discontinuation
- 2008-09-09 WO PCT/GB2008/050802 patent/WO2009034380A1/en not_active Ceased
- 2008-09-09 TW TW097134582A patent/TW200924766A/zh unknown
- 2008-09-09 AT AT08806636T patent/ATE539056T1/de active
- 2008-09-10 CL CL2008002689A patent/CL2008002689A1/es unknown
- 2008-09-10 AR ARP080103926A patent/AR071245A1/es unknown
- 2008-09-10 UY UY31334A patent/UY31334A1/es unknown
- 2008-09-11 PE PE2008001586A patent/PE20091090A1/es not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997016192A1 (en) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine antagonists |
| WO2005042517A2 (en) * | 2003-11-03 | 2005-05-12 | Schering Corporation | Bipiperidinyl derivatives useful as inhibitors of chemokine receptors |
| WO2007036711A1 (en) * | 2005-09-30 | 2007-04-05 | Glaxo Group Limited | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008299604A1 (en) | 2009-03-19 |
| TW200924766A (en) | 2009-06-16 |
| BRPI0816331A2 (pt) | 2015-04-14 |
| CA2699286A1 (en) | 2009-03-19 |
| WO2009034380A1 (en) | 2009-03-19 |
| EP2197843B1 (en) | 2011-12-28 |
| RU2010110036A (ru) | 2011-10-20 |
| PE20091090A1 (es) | 2009-08-27 |
| UY31334A1 (es) | 2009-04-30 |
| CL2008002689A1 (es) | 2009-11-27 |
| ES2377772T3 (es) | 2012-03-30 |
| KR20100052528A (ko) | 2010-05-19 |
| ATE539056T1 (de) | 2012-01-15 |
| JP2010539151A (ja) | 2010-12-16 |
| EP2197843A1 (en) | 2010-06-23 |
| US20090076078A1 (en) | 2009-03-19 |
| US8119661B2 (en) | 2012-02-21 |
| CN101874020A (zh) | 2010-10-27 |
| AR071245A1 (es) | 2010-06-09 |
| MX2010002584A (es) | 2010-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101874020B (zh) | 作为毒蕈碱受体激动剂的哌啶衍生物 | |
| US20090221567A1 (en) | Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177 | |
| US7956069B2 (en) | Compounds | |
| AU2007256014B2 (en) | Muscarinic receptor agonists that are effective in the treatment of pain, Alzheimer's disease and schizophrenia | |
| CN101472917A (zh) | 作为大麻素1（cb1）受体配体的苯并咪唑5-磺酰胺衍生物 | |
| CN102015688A (zh) | 毒蕈碱性受体激动剂、组合物、治疗方法及其制备方法 | |
| US20090275574A1 (en) | Novel compounds-300 | |
| AU2014282977B2 (en) | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121107 Termination date: 20130909 |